MedTrace Logo

Mobile Lung Cancer Screening

NCT07015151 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 4312

Last updated 2025-09-09

No results posted yet for this study

Summary

Lung cancer screening using low-dose CT (LDCT) has been shown to reduce mortality in high-risk populations. In 2022, the French National Cancer Institute (INCa) issued guidelines recommending screening for individuals aged 50-74 with a history of heavy smoking, including current smokers or those who quit less than 15 years ago. A national pilot program (IMPULSION) will be launched in 2025.

Lung cancer incidence is strongly correlated with socioeconomic status, yet underserved populations remain difficult to engage in screening programs. Mobile health units using a "reach-out" strategy have demonstrated effectiveness in other countries (UK, Brazil, USA). In France, this approach has been used for breast cancer screening via mobile mammography units.

The MobILYAD project aims to compare two screening modalities- a mobile demedicalized unit (CT-equipped van with trained nurses) and a conventional hospital-based unit- to assess the effectiveness of mobile screening in reaching socially disadvantaged populations.

Conditions

  • Lung Cancer Prevention

Interventions

DIAGNOSTIC_TEST

Low-dose Chest CT Screening

Participants undergo a low-dose chest CT scan to screen for early lung cancer and assess associated conditions (emphysema, coronary calcifications, osteoporosis).

DIAGNOSTIC_TEST

Spirometry

Assessment of lung function through spirometry, with optional plethysmography and diffusion testing to detect COPD and PRISM patterns.

DIAGNOSTIC_TEST

Cardiovascular Risk Assessment

Cardiovascular risk is evaluated using SCORE2/SCORE2-OP tools, based on blood pressure and cholesterol levels.

BEHAVIORAL

Smoking Cessation Support

Active smokers receive a structured smoking cessation intervention, including a baseline consultation and up to two follow-up sessions (which may be remote).

OTHER

Optional Biospecimen Collection (Bio-ILYAD)

Optional collection of blood and exhaled breath condensate for future analysis of biomarkers in lung cancer detection.

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-12
Primary Completion
2028-09-30
Completion
2028-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07015151 on ClinicalTrials.gov